- Home
- AMGN vs SPGI Comparison
AMGN vs SPGI Comparison
Compare AMGN & SPGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- SPGI
- Stock Information
- Founded
- AMGN 1980
- SPGI 1860
- Country
- AMGN United States
- SPGI United States
- Employees
- AMGN N/A
- SPGI N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- SPGI Finance: Consumer Services
- Sector
- AMGN Health Care
- SPGI Finance
- Exchange
- AMGN Nasdaq
- SPGI Nasdaq
- Market Cap
- AMGN 152.1B
- SPGI 150.8B
- IPO Year
- AMGN N/A
- SPGI N/A
- Fundamental
- Price
- AMGN $278.76
- SPGI $503.02
- Analyst Decision
- AMGN Buy
- SPGI Buy
- Analyst Count
- AMGN 22
- SPGI 14
- Target Price
- AMGN $334.58
- SPGI $581.25
- AVG Volume (30 Days)
- AMGN 2.5M
- SPGI 1.3M
- Earning Date
- AMGN 10-30-2024
- SPGI 10-24-2024
- Dividend Yield
- AMGN 3.23%
- SPGI 0.72%
- EPS Growth
- AMGN N/A
- SPGI 46.60
- EPS
- AMGN 7.83
- SPGI 11.32
- Revenue
- AMGN $32,534,000,000.00
- SPGI $13,768,000,000.00
- Revenue This Year
- AMGN $20.06
- SPGI $14.61
- Revenue Next Year
- AMGN $3.50
- SPGI $6.37
- P/E Ratio
- AMGN $35.59
- SPGI $44.45
- Revenue Growth
- AMGN 21.25
- SPGI 12.10
- 52 Week Low
- AMGN $260.52
- SPGI $407.53
- 52 Week High
- AMGN $346.85
- SPGI $533.29
- Technical
- Relative Strength Index (RSI)
- AMGN 22.11
- SPGI 50.01
- Support Level
- AMGN $293.80
- SPGI $477.29
- Resistance Level
- AMGN $328.25
- SPGI $515.80
- Average True Range (ATR)
- AMGN 8.26
- SPGI 8.29
- MACD
- AMGN -4.08
- SPGI 2.09
- Stochastic Oscillator
- AMGN 4.26
- SPGI 66.81
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About SPGI S&P Global Inc.
S&P Global provides data and benchmarks to capital and commodity market participants. Its ratings business is the largest credit rating agency in the world and S&P's largest segment by profitability. S&P's largest segment by revenue is market intelligence, which provides desktop, data and advisory solutions, enterprise solutions, and credit/risk solutions mostly in the financial-services industry. S&P's other segments include commodity insights (Platts and other data), mobility (Carfax), and indexes.